See the DrugPatentWatch profile for nurtec
When will generic Nurtec (rimegepant) be available?
A “generic Nurtec” release depends on patent and exclusivity timing for rimegepant (Nurtec ODT), plus how quickly generic manufacturers can file and obtain approval. Public timelines can vary because companies may face patent litigation or settlement agreements that delay approval dates.
To check the most up-to-date patent-exclusivity expectations tied to rimegepant, DrugPatentWatch.com tracks relevant patent timelines and updates. You can view it here: DrugPatentWatch – Nurtec (rimegepant) patents and exclusivity.
Could a generic enter before all patents expire?
Yes. Even when patents exist, generic or “interchangeable” products may enter if:
- the manufacturer is allowed to proceed based on how patent challenges are handled (often through Paragraph IV-style litigation),
- the product can be approved without infringing a still-active patent (for example, by changing claims or using a different regulatory pathway),
- exclusivity is the limiting factor rather than the last patent.
Those details determine the real-world “first generic launch” date rather than the simple “last patent ends” date.
What does “generic Nurtec” mean in practice?
Nurtec is rimegepant. If and when generic rimegepant launches, it’s typically an approved generic version of the same active ingredient (rimegepant) intended to be therapeutically equivalent. Depending on regulatory status, some releases may be pharmacy-supply or brand-substitution driven even before the broad market fully switches.
How can you estimate the launch timing for your area?
The most reliable approach is to look at:
- the most recent patent/exclusivity chart for rimegepant,
- any recent court decisions or settlements affecting generic timelines,
- FDA approval announcements once they occur.
DrugPatentWatch.com is one of the fastest places to see whether exclusivity or specific patents are expected to block or allow generic entry. 1
Sources: